Abstract
Sex differences in chemotherapy completion and adverse events among patients with colon cancer (CALGB/SWOG 80702) (Alliance)
Journal of clinical oncology, Vol.43(16_suppl), pp.3624-3624
06/2025
DOI: 10.1200/JCO.2025.43.16_suppl.3624
Abstract
3624
Background: Increasing chemotherapy completion and reducing chemotherapy adverse events (AE) are critical to improve survival after colon cancer diagnosis. Sex, as a biological variable, may impact chemotherapy treatment differently, and thus further investigation is needed to examine sex differences in chemotherapy completion and adverse events among patients with colon cancer. Methods: Among an NCI-sponsored trial conducted among patients with stage III colon cancer (CALGB/SWOG 80702), all patients received standard adjuvant chemotherapy FOLFOX (fluorouracil, leucovorin, and oxaliplatin). To signal chemotherapy completion, we utilized relative dose intensity (RDI) calculated as the ratio of the delivered dose intensity to planned dose intensity; and reduced RDI (RDI <85%) was considered as a clinically significant deviation from standard FOLFOX. From clinicians’ records of NCI’s Common Terminology Criteria for Adverse Events (CTCAE), we primarily focused on clinically significant AE such as neutrophils decrease, nausea, platelets decrease, hypertension, peripheral neuropathy, diarrhea, fatigue, gastritis, creatinine increase, gastric ulcer, myocardial ischemia, and cerebral ischemia; and severe AE was defined as the occurrence of any above AE with CTCAE grade ≥3. Using multivariable logistic regression that adjusted for body surface area (BSA) and other clinicopathological confounders, we estimated adjusted odds ratios (OR) for the associations of sex with reduced RDI and severe AE. Results: Of 2201 patients, mean (standard deviation [SD]) age was 60.9 (10.9) years, 1019 (46.3%) were female, 1750 (79.5%) were White, 172 (7.8%) were Hispanic, 964 (43.8%) experienced reduced RDI, and 1156 (52.5%) had severe adverse events. Compared to males, females were at significantly higher risks of experiencing reduced RDI (OR [95% CI]: 1.57 [1.27-1.93], P <0.001) and severe AE (OR [95% CI]: 1.73 [1.41-2.12], P <0.001). Conclusions: Our findings suggested females are more likely than men to experience reduced RDI and severe AE during colon cancer chemotherapy. Clinical Impact: In the era of precision medicine, sex (as a biological variable) should be considered in optimizing colon cancer chemotherapy to improve completion and reduce toxicities. Clinical trial information: NCT01150045 .
Details
- Title: Subtitle
- Sex differences in chemotherapy completion and adverse events among patients with colon cancer (CALGB/SWOG 80702) (Alliance)
- Creators
- En Cheng - Albert Einstein College of MedicineQian Shi - Mayo ClinicAnthony F. Shields - The Barbara Ann Karmanos Cancer InstituteChaoyuan Kuang - Montefiore Medical CenterArdaman Shergill - University of ChicagoChao Ma - Dana-Farber Cancer InstituteKatherine A. Guthrie - Fred Hutch Cancer CenterFelix Couture - Hôtel-Dieu de QuébecJ. Phillip Kuebler - Columbus Community Clinical Oncology ProgramPankaj Kumar - Illinois CancerCareBenjamin R. Tan - Washington University in St. LouisSmitha S. Krishnamurthi - Cleveland ClinicKimmie Ng - Dana-Farber Cancer InstituteEileen M. O'ReillyJustin Brown - Pennington Biomedical Research CenterPhilip A. Philip - The Barbara Ann Karmanos Cancer InstituteJeffrey A. Meyerhardt - Dana-Farber Cancer Institute
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.43(16_suppl), pp.3624-3624
- DOI
- 10.1200/JCO.2025.43.16_suppl.3624
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 06/2025
- Academic Unit
- Biostatistics; Endocrinology and Metabolism; Internal Medicine
- Record Identifier
- 9984845633602771
Metrics
1 Record Views